ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Approach To Improve Solubility And Bioavailability: Spray Drying

  Spray dryers today support the development of some of the most advanced drug formulations, meeting the most precise morphological requirements to ensure performance, stability, and manufacturability.

• How Various Clinical Study Stages Influence Oral Formulation Approach

  It’s important for pharmaceutical and biopharmaceutical companies to implement a phase-appropriate approach for early formulation development and later-stage commercial development.

• Making The Right Choice For Multiparticulate Modified Release Dosage Forms

  Wurster processing is a versatile pharmaceutical development and manufacturing technique for multiparticulates in modified release dosage forms. Understand if it's the right method for your modified-release project.

• Compliance Considerations For Emergency-Use Delivery Systems

  Because auto-injectors are typically the delivery device of choice for emergency medications, they come with increased scrutiny from regulatory bodies regarding their safety and effectiveness.

• Responding To Trends In Prefilled Delivery: Component Assessment And Selection

  Existing plunger technology for PFS was developed for manual injection and does not meet the evolving requirements for drug delivery especially for consistency of injection rate.

• Solutions For Challenging Compounds Using Softgel Innovation

  The significant interest in semi-solid systems for the potential of extended release profiles has prompted researchers to develop alternative encapsulating systems. 

• Selecting Container Closure Components: A Data-Driven Approach To CCI

  Discover an efficient, data-driven process that employs innovative methods to accelerate the selection of a closure containment system that meets the requirements of the modern regulatory landscape.

• Customized Release Through Dispersed Dosage Formats

  Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.

• Key Financial Considerations For Phase II Clinical Injectable Drug Manufacturing

  This article highlights the importance of scalability and flexibility in the choice of an early-stage manufacturing strategy and how that decision impacts financial outcomes for a drug development program.

• A New Framework For Identifying Nitrosamine Risks And Derisking Products

  Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.